Cannabinoids and neuroprotection in CNS inflammatory disease.
The current failure of potent immunosuppressive agents to control progressive disease in multiple sclerosis has moved a focus from immunotherapy towards the need for neuroprotection. There is increasing evidence for cannabinoid-mediated control of symptoms, which is being more supported by the underlying biology. However there is accumulating evidence in vitro and in vivo to support the hypothesis that the cannabinoid system can limit the neurodegenerative possesses that drive progressive disease, and may provide a new avenue for disease control.
Jackson
Samuel J
SJ
Department of Neuroinflammation, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ, UK. samuel.jackson@ucl.ac.uk
Diemel
Lara T
LT
Pryce
Gareth
G
Baker
David
D
D000818:Animals; D002186:Cannabinoids / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000517:prevention & control*; D004195:Disease Models, Animal; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control; D009103:Multiple Sclerosis / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use*
D002186:Cannabinoids; D018696:Neuroprotective Agents